Unlocking Cancer’s Genetic Code: New Method Reveals Hidden Editing Processes

Cancer arises from alterations in genes that control cell growth and division. Still, a new study published in Nature Communications reveals that how these genetic instructions are modified before becoming proteins as well plays a critical role in tumor development. Researchers have developed a method to directly measure this editing process, called splicing, offering a clearer understanding of how tumors reorganize their genetic activity and identifying potential new therapeutic targets.

The Role of Splicing in Cancer Development

Inside each cell, genetic instructions are first copied from DNA into RNA, creating temporary messages. Before these messages are used to build proteins, the cell edits them by removing certain segments and joining others. This process, known as splicing, allows a single gene to produce different proteins, a crucial mechanism for complex organisms.

Most cancers disrupt the splicing process, altering how these messages are assembled. This leads to the production of protein variants that can accelerate cancer cell growth, help tumors evade the immune system, or contribute to treatment resistance.

A New Approach to Mapping Genetic Editing

Traditionally, researchers have focused on splicing factors – the molecules that carry out the editing process. However, the activity of these factors can be influenced by hidden mechanisms, such as protein degradation or relocation within the cell, making it difficult to get a complete picture of gene editing.

The research team at the Center for Genomic Regulation (CRG) in Barcelona, in collaboration with Columbia University, took a different approach. Instead of measuring the splicing factors themselves, they directly analyzed the changes produced in the genetic messages. They adapted a technology called VIPER to identify which segments of RNA messages are preserved and which are removed, creating a “fingerprint” of genetic editing activity.

This method can be applied to existing RNA sequencing data, allowing researchers to analyze thousands of samples without additional experiments.

Identifying Common Editing Programs in Cancer

The researchers applied the VIPER method to approximately 10,000 tumor biopsies from 14 different cancer types, using data from The Cancer Genome Atlas, a public database. By comparing tumor samples to corresponding healthy tissue, they identified two major cellular editing programs consistently present across all cancers studied.

• Accelerator Program: This program becomes more active in tumors and is associated with poorer patient outcomes.
• Braking Mechanism: This program’s activity decreases in cancer and is linked to better survival rates.

This discovery suggests that despite the diversity of cancer types, they may share common strategies for reorganizing gene editing processes.

Potential Therapeutic Targets and Future Applications

Analyzing the biological factors influencing these editing programs, the researchers identified around 100 potential therapeutic targets – molecules that could be regulated to restore balance to genetic editing mechanisms. One notable candidate was the FUS gene, known for its role in neurological conditions, suggesting a potential new avenue for oncology research.

The researchers believe this method could extend beyond cancer research. Because it analyzes the result of gene editing, rather than its specific cause, it could be used to study diseases where cells alter their genetic message assembly, including neurological disorders and immune system diseases.

“We started with cancer because there was data available, but this approach could work for any disease where cells change the way they edit their genetic messages, including in neurological disorders or diseases of the immune system,” said Dr. Miquel Anglada Girotto, first author of the study and postdoctoral researcher at CRG. Nature Communications